DDInter564 DDInter1657
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide]. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Dimethyl fumarate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Dimethyl fumarate {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Dimethyl fumarate may lead to a major life threatening interaction when taken with Tofacitinib
Dimethyl fumarate may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live